The AMR Action Fund hopes to be operational by the end of 2020 and begin reviewing novel antibiotic candidates to invest in during the first quarter of 2021, interim general manager Martin Bott told the virtual BIO Investor Forum on 13 October. Its focus will be on mid-stage antibiotic candidates, leaving earlier investment support to other groups.
The fund has been in planning since mid-2019, arising from discussions at an international conference, and was unveiled in July....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?